Sugi Predict

Sugi Predict / Targets / NR4A3

NR4A3

Nuclear receptor subfamily 4 group A member 3 · Q92570 · NR4A3 on Sugi Atlas →

27,943 patent compounds predicted against NR4A3, 21,139 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL330227 SCHEMBL330227 0.50 3/20
SCHEMBL419050 SCHEMBL419050 0.55 2/20
SCHEMBL228601 SCHEMBL228601 0.51 2/20
Oxaprozin Oxaprozin (SCHEMBL3286) 1.00 1/20
Naphthoic Acid Naphthoic Acid (SCHEMBL17258) 1.00 1/20
SCHEMBL228477 SCHEMBL228477 1.00 1/20
Vidofludimus Vidofludimus (SCHEMBL247888) 1.00 1/20
Oxaprozin Oxaprozin (SCHEMBL137988) 0.97 1/20
Naphthoic Acid Naphthoic Acid (SCHEMBL56567) 0.95 1/20
Naphthoic Acid Naphthoic Acid (SCHEMBL201658) 0.95 1/20
SCHEMBL254247 SCHEMBL254247 0.79 1/20
Naphthoic Acid Naphthoic Acid (SCHEMBL81715) 0.78 1/20
SCHEMBL402300 SCHEMBL402300 0.77 1/20
SCHEMBL42302 SCHEMBL42302 0.74 1/20
SCHEMBL119689 SCHEMBL119689 0.74 1/20
SCHEMBL228290 SCHEMBL228290 0.74 1/20
SCHEMBL253900 SCHEMBL253900 0.74 1/20
SCHEMBL27985 SCHEMBL27985 0.73 1/20
SCHEMBL50807 SCHEMBL50807 0.72 1/20
SCHEMBL254715 SCHEMBL254715 0.72 1/20

Clinical trials — most relevant to NR4A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Effect of Metformin in Children With Type 1 Diabetes PHASE2/PHASE3COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Effects of Advair® in Outpatients With Chronic Obstructive Pulmonary Disease (COPD) Acute Exacerbation PHASE3COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease PHASE2COMPLETED
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease PHASE2COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) PHASE2UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Meclizine for Hepatocellular Carcinoma PHASE1COMPLETED
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients EARLY_PHASE1RECRUITING
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer nanUNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Potential Role of Inflammasome NLRP3 And IL-1B Gene Expression in COVID-19 Patients: Impact of Ferretin and D -Dimer. nanUNKNOWN
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases nanCOMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients nanNOT_YET_RECRUITING
Assessment of Novel Sound Changing Principles in Hearing Instruments to Determine Their Application - 2019_20 nanCOMPLETED
Study to Evaluate the Effect of Nicotinamide Riboside on Immunity nanCOMPLETED
Early Parenting Intervention: Bio-behavioral Outcomes in Infants With Neurodevelopmental Disabilities nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NR4A3 binder may also engage these)

ProteinNameSimilarity
P51179 — 1.000 P51179 →
Q9QZB6 — 1.000 Q9QZB6 →
Q05192 — 0.999 Q05192 →
P19091 — 0.999 P19091 →
P12813 — 0.999 P12813 →
P51128 — 0.998 P51128 →
P49699 — 0.998 P49699 →
O97960 — 0.998 O97960 →
P50569 — 0.998 P50569 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.998 landscape →
RXRB Retinoic acid receptor RXR-beta 0.998 landscape →
O97775 — 0.997 O97775 →
Q3UV55 — 0.997 Q3UV55 →
Q64249 — 0.997 Q64249 →
P33242 — 0.997 P33242 →
P28700 — 0.997 P28700 →
Q6QT55 — 0.997 Q6QT55 →
P22829 — 0.997 P22829 →
Q9GKL7 — 0.997 Q9GKL7 →
NR5A1 Steroidogenic factor 1 0.997 landscape →
P06537 — 0.997 P06537 →
Q6F2E4 — 0.997 Q6F2E4 →
O97952 — 0.997 O97952 →
Q9XYB7 — 0.997 Q9XYB7 →
Q95RW8 — 0.996 Q95RW8 →
P24610 — 0.996 P24610 →
H2KYJ8 — 0.996 H2KYJ8 →
P51129 — 0.996 P51129 →
Q95L87 — 0.996 Q95L87 →
Q07917 — 0.996 Q07917 →